8-K filing — Metagenomi Therapeutics, Inc. (MGX)
Filed: 2026-09-22 AccNo: 0001193125-26-397037 Size: 10 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
Metagenomi Therapeutics announced that CEO Jian Irish will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026. The company remains on track to submit an IND application in Q4 2026 for MGX-001, its lead hemophilia A treatment program utilizing proprietary CRISPR gene-editing technology.
Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M Estimate
Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.57) by 28.07 percent. This is a 35.19 percent decrease over losses of $(0.54) per share from the